Antiplatelet agents make a comeback in ST-elevation myocardial infarction

Stephen D. Wiviott, James A de Lemos

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although data from CLARITY-TIMI 28 and COMMIT/CCS-2 affirm the importance of antiplatelet agents as adjuncts to fibrinolytic therapy in STEMI, several questions remain. Novel antiplatelet agents have attractive properties for use in STEMI such as rapid onset, higher and more consistent levels of platelet inhibition, and in some cases rapid offset. Although lessons from the past suggest caution before embracing potent antiplatelet agents in STEMI, current data with clopidogrel coupled with potential pharmacologic advantages of newer agents may signal a bright future for adjunctive antiplatelet agents in STEMI.

Original languageEnglish (US)
Pages (from-to)603-606
Number of pages4
JournalAmerican Heart Journal
Volume154
Issue number4
DOIs
StatePublished - Oct 2007

Fingerprint

Platelet Aggregation Inhibitors
clopidogrel
Thrombolytic Therapy
Blood Platelets
ST Elevation Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antiplatelet agents make a comeback in ST-elevation myocardial infarction. / Wiviott, Stephen D.; de Lemos, James A.

In: American Heart Journal, Vol. 154, No. 4, 10.2007, p. 603-606.

Research output: Contribution to journalArticle

@article{e7e07975942846cea6b694b68fa88559,
title = "Antiplatelet agents make a comeback in ST-elevation myocardial infarction",
abstract = "Although data from CLARITY-TIMI 28 and COMMIT/CCS-2 affirm the importance of antiplatelet agents as adjuncts to fibrinolytic therapy in STEMI, several questions remain. Novel antiplatelet agents have attractive properties for use in STEMI such as rapid onset, higher and more consistent levels of platelet inhibition, and in some cases rapid offset. Although lessons from the past suggest caution before embracing potent antiplatelet agents in STEMI, current data with clopidogrel coupled with potential pharmacologic advantages of newer agents may signal a bright future for adjunctive antiplatelet agents in STEMI.",
author = "Wiviott, {Stephen D.} and {de Lemos}, {James A}",
year = "2007",
month = "10",
doi = "10.1016/j.ahj.2005.04.036",
language = "English (US)",
volume = "154",
pages = "603--606",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Antiplatelet agents make a comeback in ST-elevation myocardial infarction

AU - Wiviott, Stephen D.

AU - de Lemos, James A

PY - 2007/10

Y1 - 2007/10

N2 - Although data from CLARITY-TIMI 28 and COMMIT/CCS-2 affirm the importance of antiplatelet agents as adjuncts to fibrinolytic therapy in STEMI, several questions remain. Novel antiplatelet agents have attractive properties for use in STEMI such as rapid onset, higher and more consistent levels of platelet inhibition, and in some cases rapid offset. Although lessons from the past suggest caution before embracing potent antiplatelet agents in STEMI, current data with clopidogrel coupled with potential pharmacologic advantages of newer agents may signal a bright future for adjunctive antiplatelet agents in STEMI.

AB - Although data from CLARITY-TIMI 28 and COMMIT/CCS-2 affirm the importance of antiplatelet agents as adjuncts to fibrinolytic therapy in STEMI, several questions remain. Novel antiplatelet agents have attractive properties for use in STEMI such as rapid onset, higher and more consistent levels of platelet inhibition, and in some cases rapid offset. Although lessons from the past suggest caution before embracing potent antiplatelet agents in STEMI, current data with clopidogrel coupled with potential pharmacologic advantages of newer agents may signal a bright future for adjunctive antiplatelet agents in STEMI.

UR - http://www.scopus.com/inward/record.url?scp=34548720479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548720479&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2005.04.036

DO - 10.1016/j.ahj.2005.04.036

M3 - Article

C2 - 17892976

AN - SCOPUS:34548720479

VL - 154

SP - 603

EP - 606

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -